At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps can provide the best returns over the long term due to the fact that these companies are less efficiently priced and are usually under the radars of mass-media, analysts and dumb money. This is why we follow the smart money moves in the small-cap space.
Acceleron Pharma Inc (NASDAQ:XLRN) investors should pay attention to an increase in support from the world’s most elite money managers recently. XLRN was in 22 hedge funds’ portfolios at the end of September. There were 21 hedge funds in our database with XLRN holdings at the end of the previous quarter. At the end of this article we will also compare XLRN to other stocks including The Buckle, Inc. (NYSE:BKE), Endurance International Group Hldgs Inc (NASDAQ:EIGI), and Globalstar, Inc. (PINK:GSAT) to get a better sense of its popularity.
Follow Acceleron Pharma Inc (NASDAQ:XLRN)
Follow Acceleron Pharma Inc (NASDAQ:XLRN)
At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.
Nata-Lia/Shutterstock.com
Keeping this in mind, we’re going to go over the recent action surrounding Acceleron Pharma Inc (NASDAQ:XLRN).
What have hedge funds been doing with Acceleron Pharma Inc (NASDAQ:XLRN)?
Heading into the fourth quarter of 2016, a total of 22 of the hedge funds tracked by Insider Monkey were bullish on this stock, up 5% from the second quarter of 2016. With hedge funds’ sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).
When looking at the institutional investors followed by Insider Monkey, Benjamin A. Smith’s Laurion Capital Management has the most valuable position in Acceleron Pharma Inc (NASDAQ:XLRN), worth close to $25 million, accounting for 0.2% of its total 13F portfolio. On Laurion Capital Management’s heels is QVT Financial, managed by Daniel Gold, which holds a $23 million position; the fund has 0.9% of its 13F portfolio invested in the stock. Some other peers with similar optimism encompass Joseph Edelman’s Perceptive Advisors, Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management and Peter Kolchinsky’s RA Capital Management.
